Topic: Bladder Cancer

Bladder Cancer and Immunotherapy

Jennifer M. Taylor, MD, MPH, provides a brief overview of the basic scientific concepts of cancer cell suppression with checkpoint inhibitors. She also reviews the initial clinical trials for atezolizumab and pembrolizumab, larger trials for various immunotherapies for bladder cancer, toxicity reports, and ongoing research regarding these drugs in different combinations and disease states.

Read More

Controversies in Non-Muscle Invasive Bladder Cancer

Siamak Daneshmand, MD, reports on recent controversies in treatment for non-muscle invasive bladder cancer (NMIBC) regarding chemotherapy options for reducing post-transurethral resection (TUR) recurrences and active surveillance for low-grade patients, as well as alternatives to cystectomy in high-grade patients.

Read More

Updates on Immunotherapy for Bladder Cancer

Daniel P. Petrylak, MD, discusses new treatments for metastatic bladder cancer and the importance of accurate PD-L1 markers. He also offers his predictions for bladder cancer checkpoint inhibitor therapy and second-line agents for patients who do not respond to checkpoint inhibitors.

Read More

A Biodynamic Imaging Platform for Bladder Cancer

Jeff Fensterer, Vice President of Marketing Strategy at Animated Dynamics, Inc., introduces a biodynamic imaging platform for bladder cancer that is currently under development. The assay could have clinical utility in selecting patients for neoadjuvant chemotherapy, as well as in treatment planning.

Read More

En Bloc TURB – More Than a Safe and Feasible Surgical Technique

Salvatore Micali, MD, discusses the pros and cons of en bloc transurethral resection of bladder (TURB) and its advantages over classical TURB. Specifically, he describes how en bloc TURB lends itself to correct specimen orientation, easier identification of the tumor growth front and whether the disease has invaded the chorion, and better determination of the deep surgical margin.

Read More

Join the GRU Community

- Why Join? -